Post date: 9 months 3 weeks ago

Spend a week, April 12-16, 2021, in our live virtual mentoring with top medication safety leaders. Participants will learn how to build a resilient medication safety infrastructure and gain insights on addressing contemporary safety challenges in their own organizations. No travel required! Even online, the number of registrants is limited to allow for dedicated attention to your learning needs. Save your space by signing up soon:

Post date: 10 months 1 week ago

ISMP has published a list of the top 10 medication errors and issues covered in the acute care newsletter in 2020. We hope that you incorporate our prevention recommendations in your organization-wide, strategic medication safety improvement plan for 2021! To view the list and access ISMP’s advice on how to manage these risks, visit:

Post date: 10 months 2 weeks ago

Prevent wrong-route errors by adopting ENfit-compliant devices in your organization! Learn how ENfit can help reduce the risk of catheter misconnections involving enteral-to-IV tubing during a free ISMP webinar on February 24, 2021 from 1:00-2:00pm ET (CE available):

Post date: 10 months 2 weeks ago

Sign up now for the next MSOS Member Briefing webinar scheduled to be held on Thursday, January 28, 2021 from 1:00-2:00 PM ET.

Register Now:

Short medication safety-related presentations for this webinar will include:
• Establishing a Medication Safety Officer in a Unique Practice Setting
Morgan Drew Greutman, Pharm.D., BCPS
Lieutenant Commander, USPHS, Medication Safety Officer
Choctaw Nation Health Services Authority

• Medication Safety Efforts in the United Kingdom
Nicola Wake BPharm, MRPharmS (IPresc)
Specialist Pharmacist: Lead Medication Safety | NHS Specialist Pharmacy Service
Lead Clinical Pharmacist: Safety & Governance | Medication Safety Officer | Northumbria Healthcare NHS Foundation Trust

Post date: 10 months 2 weeks ago

Error reporting is mandatory for therapeutic products under an Emergency Use Authorization; errors with COVID-19 vaccines must be sent to VAERS (, while errors with bamlanivimab and casirivimab/imdevimab must be reported to FDA Medwatch ( Please also inform ISMP (; your report will help us identify and communicate safety issues!